FGFR2 and breast ductal adenocarcinoma: FGFR2 has been reported in the progression of ER-negative luminal ductal carcinomas, which are more aggressive and less responsive to treatment, suggesting that FGFR2 may have an effect promoting IDC progression to an ER-independent basal-like phenotype [41,61].